Research chemicalResearch chemicalDissociativeArylcyclohexylamine

Fluorexetamine (FXE)

Also known as FXE · Fluorexetamine

Written by enwyReviewed 4 Aug 20261 sources0 comments

Fluorexetamine (FXE) is an arylcyclohexylamine dissociative in the methoxetamine/ketamine family that emerged as a research chemical around 2020. It is an NMDA receptor antagonist producing dose-dependent dissociation and anaesthesia, with a longer duration than ketamine. Human data are anecdotal, and bladder toxicity is a plausible class-shared concern.

01 Overview

Fluorexetamine is a fluorinated analogue related to methoxetamine, marketed as a longer-lasting dissociative research chemical. It has no clinical characterisation, and its profile is drawn from user reports and structural analogy to the ketamine-type dissociatives.

Reported effects are dose-dependent dissociation, analgesia and anaesthesia, with a notably long duration that raises the risk of accidental redosing. As with other ketamine-family analogues, urinary-tract and bladder toxicity is a plausible risk with heavy, frequent use, alongside ataxia and confusion.

02 Mechanism

Non-competitive NMDA receptor antagonist (open-channel blocker); a fluorinated arylcyclohexylamine in the methoxetamine/ketamine family.

03 Dosing

Tier	Dose	Route	Notes
Light	10–25 mg	Insufflated	Faster onset; poorly characterised.
Light	15–30 mg	Oral	Long onset; wait before redosing.
Common	30–60 mg	Oral	Estimated from anecdote; long duration.

04 Effects

Effect	Magnitude	Evidence
DissociationDetachment, depersonalisation and 'hole'-like states at high doses.		Anecdotal
AnalgesiaReduced pain perception at higher doses.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Ataxia and loss of coordinationUnsteady gait and impaired motor control with fall risk.	Moderate	Very common	Anecdotal
Overdose from redosingLong, delayed onset makes cumulative overdose and confusion likely if redosed.	Severe	With redosing	Unconfirmed
Bladder and urinary-tract toxicityCystitis-type bladder damage seen with ketamine and analogues may extend to FXE with frequent heavy use.	Severe	Plausible with heavy use	Unconfirmed

06 Legal status

United States

May fall under Analogue Act

as of Jan 2026

United Kingdom

Psychoactive Substances Act / analogue controls

as of Jan 2026

07 References

Fluorexetamine and novel dissociative NPSPubMed search

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.